Drugs / VARIVAX(TM)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00092391 Background | Feb 1999 → Jul 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Merck Sharp & Dohme LLC | US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗ |
| 2018-02-09 | Merck Sharp & Dohme LLC | VARIVAX, Merck’s Varicella (Chickenpox) Vaccine, Awarded WHO Pre-Qualification Status merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VARIVAX(TM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00092391 ↗ |
| Known as | Varicella Virus Vaccine Live (Oka-Merck) | “Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)” NCT00092391 ↗ |
| Modality | Vaccine | “Varicella Virus Vaccine Live (Oka-Merck)” NCT00092391 ↗ |
| Route | Subcutaneous | “0.5 mL subcutaneous injection on Day 0” NCT00092391 ↗ |